Antipsychotic-associated weight gain predisposes to development of metabolic syndrome and type 2 diabetes mellitus and thereby contributes to a decreased life span by approximately 20 years in patients with schizophrenia.
1,2 Quiz Ref ID The weight gain is mediated through complex peripheral and central mechanisms involving various neurotransmitters and neuropeptides.
3-5 Histamine H
1 receptor blockade may explain in part the pronounced weight gain often associated with clozapine and olanzapine treatment,
6-9 whereas serotonin
2A receptor blockade may be of importance in quetiapine fumarate–associated weight gain.
10 However, antipsychotics with lower histaminergic or serotonergic affinity, such as chlorpromazine hydrochloride and the relatively selective dopamine D
2 receptor antagonist amisulpride, are associated with weight gain.
11,12 This association suggests that dopamine D
2 receptor antagonism may play a critical role in antipsychotic-associated weight gain.
13,14